Quadrature Capital Ltd Takes $85,000 Position in Bioventus Inc. (NYSE:BVS)

Quadrature Capital Ltd purchased a new stake in Bioventus Inc. (NYSE:BVS) during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm purchased 16,031 shares of the company’s stock, valued at approximately $85,000.

Several other hedge funds and other institutional investors also recently made changes to their positions in the business. GSG Advisors LLC acquired a new stake in Bioventus during the fourth quarter worth about $89,000. Jump Financial LLC acquired a new stake in Bioventus during the fourth quarter worth about $122,000. Hillsdale Investment Management Inc. acquired a new stake in Bioventus during the fourth quarter worth about $145,000. Barclays PLC acquired a new stake in Bioventus during the third quarter worth about $119,000. Finally, Citigroup Inc. grew its position in Bioventus by 13,474.4% during the third quarter. Citigroup Inc. now owns 52,533 shares of the company’s stock worth $173,000 after buying an additional 52,146 shares in the last quarter. 62.94% of the stock is owned by institutional investors and hedge funds.

Bioventus Stock Performance

NYSE:BVS opened at $5.75 on Friday. Bioventus Inc. has a 1 year low of $2.71 and a 1 year high of $7.04. The firm has a 50 day moving average of $5.70 and a 200-day moving average of $5.20. The company has a current ratio of 1.53, a quick ratio of 0.97 and a debt-to-equity ratio of 1.63. The stock has a market capitalization of $455.20 million, a P/E ratio of -16.43 and a beta of 0.89.

Bioventus (NYSE:BVS) last posted its earnings results on Tuesday, May 7th. The company reported $0.07 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.05) by $0.12. Bioventus had a negative net margin of 4.14% and a positive return on equity of 11.91%. The company had revenue of $129.46 million during the quarter, compared to analysts’ expectations of $115.51 million. As a group, sell-side analysts anticipate that Bioventus Inc. will post 0.27 EPS for the current fiscal year.

Insider Activity

In related news, SVP Anthony D’adamio sold 11,308 shares of the business’s stock in a transaction that occurred on Monday, June 17th. The shares were sold at an average price of $5.84, for a total value of $66,038.72. Following the completion of the transaction, the senior vice president now owns 81,630 shares in the company, valued at approximately $476,719.20. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, SVP Anthony D’adamio sold 11,308 shares of the business’s stock in a transaction that occurred on Monday, June 17th. The shares were sold at an average price of $5.84, for a total value of $66,038.72. Following the completion of the transaction, the senior vice president now owns 81,630 shares in the company, valued at approximately $476,719.20. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Mark Leonard Singleton sold 9,219 shares of the business’s stock in a transaction that occurred on Friday, June 21st. The stock was sold at an average price of $5.57, for a total transaction of $51,349.83. Following the completion of the transaction, the chief financial officer now owns 84,895 shares of the company’s stock, valued at approximately $472,865.15. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 47,238 shares of company stock worth $264,098. Insiders own 32.90% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have commented on the stock. Craig Hallum raised their price target on shares of Bioventus from $6.00 to $9.00 and gave the stock a “buy” rating in a research note on Wednesday, March 13th. Canaccord Genuity Group raised their price target on shares of Bioventus from $7.00 to $8.00 and gave the stock a “buy” rating in a research note on Wednesday, May 8th.

Bioventus Profile

Bioventus Inc, a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain.